;
Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Neurology Eisai launched Fycompa perampanel in Belgium as adjunctive treatment of partial onset seizures, with or without secondarily generalized seizures, in …

    Published on 8/18/2014
  • Vermillion sales and marketing update

    Vermillion Inc. (NASDAQ:VRML), Austin, Texas Business: Diagnostic Vermillion said its Aspira Inc. CLIA-certified reference lab is now operational. Aspira is providing diagnostic services, including OVA1 and Longitudinal…

    Published on 8/18/2014
  • Vertex sales and marketing update

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass. Business: Infectious Vertex will discontinue sales of HCV drug Incivek telaprevir in the U.S. by Oct. 16 in light of available alternative treatments and …

    Published on 8/18/2014
  • Biotie, Lundbeck sales and marketing update

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology Biotie said partner Lundbeck launched Selincro nalmefene in Spain to help reduce alcohol consumption …

    Published on 8/11/2014
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Gilead said it expects to provide HCV drug Sovaldi sofosbuvir in India at about $300 for a four-week supply or $900 for a 12-week course of …

    Published on 8/11/2014
  • Illumina, Sidra Medical and Research Center sales and marketing update

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Sidra Medical and Research Center, Doha, Qatar Business: Genomics Sidras High-Throughput Genomics Center will offer human whole genome sequencing for rare genetic diseases …

    Published on 8/11/2014
  • Innocutis, Onxeo sales and marketing update

    Innocutis Holdings LLC, Charleston, S.C. Onxeo S.A. (Euronext:ONXEO), Paris, France Business: Infectious Innocutis launched Sitavig acyclovir 50 mg buccal tablet in North America to treat recurrent herpes labialis. …

    Published on 8/11/2014
  • Durata Therapeutics sales and marketing update

    Durata Therapeutics Inc. (NASDAQ:DRTX), Chicago, Ill. Business: Infectious Durata launched Dalvance dalbavancin in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible …

    Published on 8/4/2014
  • Novocure sales and marketing update

    Novocure Ltd., Isle of Jersey Business: Cancer Novocure launched NovoTTF Therapy in Austria, the Czech Republic, England, France, Germany, Greece, Switzerland and Israel to treat recurrent glioblastoma. The company said…

    Published on 8/4/2014
  • bioMerieux sales and marketing update

    bioMerieux S.A. (Euronext:BIM), Marcy lEtoile, France Business: Diagnostic bioMerieuxs bioTheranostics Inc. subsidiary said U.S. healthcare provider FedMed Inc. will cover genomic tests for patients with breast cancer …

    Published on 7/28/2014
  • Endo, Medigene sales and marketing update

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Medigene AG (Xetra:MDG), Martinsried, Germany Business: Infectious Endos Paladin Labs Inc. subsidiary launched Veregen sinecatechins in Canada to treat …

    Published on 7/28/2014
  • Arena, Eisai sales and marketing update

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Endocrine/Metabolic Arena said Eisai completed its increase of more than 200 sales representatives in its …

    Published on 7/21/2014
  • Enzymatics sales and marketing update

    Enzymatics Inc., Beverly, Mass. Business: Diagnostic Enzymatics launched worldwide the Archer FusionPlex Sarcoma Panel assay to detect and identify fusions of 26 genes associated with sarcoma. The assay uses Enzymatics …

    Published on 7/21/2014
  • kaleo sales and marketing update

    kaleo Inc., Richmond, Va. Business: Neurology kaleo launched Evzio naloxone in the U.S. for the emergency treatment of known or suspected opioid overdose. The product is a hand-held autoinjector that provides verbal …

    Published on 7/21/2014
  • Oxford Gene sales and marketing update

    Oxford Gene Technology, Oxford, U.K. Business: Diagnostic Oxford Gene launched the CytoSure Embryo Screen Array worldwide to improve embryo screening for in vitro fertilization (IVF). The high throughput genetic …

    Published on 7/21/2014
  • Upsher-Smith sales and marketing update

    Upsher-Smith Laboratories Inc., Maple Grove, Minn. Business: Neurology Upsher-Smith launched Qudexy XR topiramate extended-release capsules in the U.S. for seizures. Specifically, the drug is indicated as initial …

    Published on 7/21/2014
  • Veracyte sales and marketing update

    Veracyte Inc. (NASDAQ:VCYT), South San Francisco, Calif. Business: Diagnostic Veracyte said Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, both affiliates of Blue Cross Blue Shield, issued positive …

    Published on 7/21/2014
  • Nanosphere Inc, HealthTrust Purchasing Group L.P. sales and marketing update

    Nanosphere Inc. (NASDAQ:NSPH), Northbrook, Ill. HealthTrust Purchasing Group L.P., Brentwood, Tenn. Business: Diagnostic Nanosphere signed an agreement with group purchasing organization HealthTrust to provide the …

    Published on 7/14/2014
  • Otsuka Pharmaceutical Co. Ltd sales and marketing update

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Pulmonary, Inflammation Otsuka launched Meptin Swinghaler procaterol in Japan to treat chronic obstructive pulmonary disease (COPD) and asthma. Meptin Swinghaler is…

    Published on 7/14/2014
  • Takeda Pharmaceutical Co. Ltd sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cardiovascular Takeda launched Zacras azilsartan/amlodipine besylate in Japan to treat hypertension. The once-daily, fixed-dose combination of …

    Published on 7/14/2014
  • Apricus Biosciences, Takeda sales and marketing update

    Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Genitourinary Apricus said partner Takeda launched Vitaros alprostadil in the U.K. to treat …

    Published on 6/30/2014
  • Azanta, Medigene, Will-Pharma sales and marketing update

    Azanta A/S, Hellerup, Denmark Medigene AG (Xetra:MDG), Martinsried, Germany Will-Pharma, Wavre, Belgium Business: Infectious Medigene said partner Will-Pharma launched Veregen sinecatechins in Belgium to treat genital…

    Published on 6/30/2014
  • bioMerieux, Quest Diagnostics sales and marketing update

    bioMerieux S.A. (Euronext:BIM), Marcy lEtoile, France Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Pharmacogenetics Quest launched bioMerieuxs THxID BRAF test in the U.S. to detect BRAF V600E and V600K …

    Published on 6/30/2014
  • Medivir sales and marketing update

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Infectious Medivir launched Olysio simeprevir in Sweden, Finland and Denmark and said the HCV drug will be available in all Nordic countries within the next few weeks…

    Published on 6/30/2014
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune Takeda launched Entyvio vedolizumab in the U.S. to treat moderate to severe ulcerative colitis (UC) and moderate to severe Crohns disease (…

    Published on 6/30/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993